Skip to Content

Giulio F. Draetta, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Director, MD Anderson Institute for Applied Cancer Science, Houston, TX
Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
VP, ad interim, Therapeutics Discovery, The University of Texas MD Anderson Cancer Center, Houston, TX
Co-Leader, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston

Education & Training

Degree-Granting Education

1985 University of Naples Medical School, Naples, Italy, PHD, Clinical Pathology and Biochemistry
1981 University of Naples Medical School, Naples, Italy, MD, summa cum laude, Medicine

Postgraduate Training

1986-1987 Robertson Fellow, Cold Spring Harbor Laboratory, New York, NY, David Beach, Ph.D.
1983-1986 Fogarty International Center Fellow, National Institutes of Health, National Cancer Institute, Laboratory of Biochemistry, Bethesda, MD
1982-1983 Clinical Fellow, University of Naples Medical School, Naples, Italy
1976-1981 Intern, Institute of Biochemistry, Medical School, Naples, Italy


Academic Appointments

Professor, Department of Genomic Medicine, Division of Cancer Medicine, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 9/2012-present
Professor of Biochemistry, University of Milan, Bicocca, Milan, Italy, 1999

Administrative Appointments/Responsibilities

VP for Operations, Strategic Research Programs ad interim, The University of Texas MD Anderson Cancer Center, Houston, TX, 5/2013-6/2016
Deputy Director for Science, Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, 2008-2011
Vice-President and Worldwide Basic Franchise Head, Oncology, Merck Research Laboratories, Boston, MA, 2007-2008
Executive Director and Worldwide Head, Basic Research, Merck Research Laboratories, Boston, MA, 2004-2006
Executive Director, Cancer Research, Merck Research Laboratories, Pomezia, Italy, 2004
Vice President and Head, Oncology R&D, Nerviano Medical Science (NMS), Nerviano, Milan, Italy, 2004
Executive Director and Site Head, Pharmacia Discovery Research Europe, Milan, Italy, 2002-2004
Director and Site Head, Pharmacia Oncology Research, Milan, Italy, 2002
Director, Therapeutic Area Team, Pharmacia Oncology, Milan, Italy, 2001
Director, Department of Worldwide Oncology Pharmacology, Pharmacia & Upjohn Oncology Research, Milan, Italy, 1999-2000

Other Appointments/Responsibilities

Chief Research Business Development Officer, Dana-Farber Cancer Institute, Boston, MA, 2009-2011
Presidential Scholar, Dana-Farber Cancer Institute, Boston, MA, 2008-2011
Founding Member and Division Director of the Department of Experimental Oncology, European Institute of Oncology, Milan, Italy, 1996-1999
Founder and Vice President, Biological Research, Mitotix, Inc., Cambridge, MA, 1993-1995

Selected Publications

Peer-Reviewed Original Research Articles

1. Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, Kost-Alimova M, Muller F, Colla S, Nezi L, Genovese G, Deem AK, Kapoor A, Yao W, Brunetto E, Kang Y, Yuan M, Asara JM, Wang YA, Heffernan TP, Kimmelman AC, Wang H, Fleming JB, Cantley LC, DePinho RA, Draetta GF. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514(7524):628-32, 10/30/2014. e-Pub 8/10/2014. PMID: 25119024.
2. Kapoor A, Yao W, Ying H, Hua S, Liewen A, Wang Q, Zhong Y, Wu CJ, Sadanandam A, Hu B, Chang Q, Chu GC, Al-Khalil R, Jiang S, Xia H, Fletcher-Sananikone E, Lim C, Horwitz GI, Viale A, Pettazzoni P, Sanchez N, Wang H, Protopopov A, Zhang J, Heffernan T, Johnson RL, Chin L, Wang YA, Draetta G, DePinho RA. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 158(1):185-197, 7/2014. e-Pub 6/2014. PMCID: PMC4109295.
3. Draetta GF, Depinho RA. Cancer Drug Discovery Faces the FACT. Sci Transl Med 3(95):95ps34, 8/10/2011. PMID: 21832237.
4. Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, Gargano D, Shomer NH, Angagaw M, Leccese E, Andrade P, Hurd M, Shin MK, Vogt TF, Northrup A, Bobkova EV, Kasibhatla S, Bronson RT, Scott ML, Draetta G, Richon V, Kohl N, Blume-Jensen P, Andersen JN, Kraus M. PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 71(8):3052-65, 4/15/2011. PMID: 21493594.
5. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, Godinho SI, Draetta GF, Pagano M. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science 316(5826):900-4, 5/2007. e-Pub 4/2007. PMID: 17463251.
6. Squatrito M, Mancino M, Donzelli M, Areces LB, Draetta GF. EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 23(25):4454-65, 5/27/2004. PMID: 15064750.
7. Donzelli M, Busino L, Chiesa M, Ganoth D, Hershko A, Draetta GF. Hierarchical order of phosphorylation events commits Cdc25A to betaTrCP-dependent degradation. Cell Cycle 3(4):469-71, 4/2004. e-Pub 4/1/2004. PMID: 14752276.
8. Busino L, Donzelli M, Chiesa M, Guardavaccaro D, Ganoth D, Dorrello NV, Hershko A, Pagano M, Draetta GF. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426(6962):87-91, 11/6/2003. PMID: 14603323.
9. Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 13(9):1181-9, 5/1999. PMCID: PMC316946.
10. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3(2):231-4, 2/1997. PMID: 9018245.
11. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269(5224):682-5, 8/1995. PMID: 7624798.
12. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 13(18):4302-10, 9/1994. PMCID: PMC395357.
13. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7(5):812-21, 5/1993. PMID: 8491378.
14. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 12(1):53-63, 1/1993. PMCID: PMC413175.
15. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 11(3):961-71, 3/1992. PMCID: PMC556537.
16. Draetta G, Piwnica-Worms H, Morrison D, Druker B, Roberts T, Beach D. Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature 336(6201):738-44, Dec 22-29, 12/22/1988. PMID: 2462672.
17. Draetta G, Beach D. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. Cell 54(1):17-26, 7/1988. PMID: 3289755.
18. Draetta G, Brizuela L, Potashkin J, Beach D. Identification of p34 and p13, human homologs of the cell cycle regulators of fission yeast encoded by cdc2+ and suc1+. Cell 50(2):319-25, 7/17/1987. PMID: 3297353.

Grant & Contract Support

Title: Identifying new epigenetic vulnerabilities in pancreatic cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2016 - 2/28/2019
Title: Pancreatic Cancer Moon Shot
Funding Source: UT MD Anderson Cancer Center/Philanthropic Gifts
Role: Co-Principal Investigator
Principal Investigator: Wolff, Fleming, Maitra
Duration: 9/1/2014 - 8/31/2019
Title: The Nexus of Epigenetics and Immune-oncology: Translational Research to Develop Combined Therapies
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator
Duration: 9/1/2014 - 8/31/2016
Title: The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer Developmental Research Project: In vivo selection for novel co-extinction targets to enhance the activity of PARP inhibitors in ovarian cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Robert Bast
Duration: 9/1/2014 - 8/31/2015
Title: Developing a novel oxidative phosphorylation inhibitor in pancreatic cancer
Funding Source: American Association for Cancer Research (AACR)
Role: Co-Principal Investigator
Duration: 7/1/2014 - 6/30/2017
Title: CCSG Multidisciplinary Research Program
Funding Source: NIH/NCI
Role: Program Leader
Principal Investigator: DePinho
Duration: 3/1/2014 - 2/28/2017
Title: SPORE in Brain Cancer, Project 2: Targeting th ePI3K pathway in malignant glioma
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: Lang/Fueyo
Duration: 9/1/2013 - 8/31/2018
Title: Cancer Center Support Grant-Targeted Therapy Program
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: William Plunkett
Duration: 7/1/2013 - 6/30/2018
Title: Eradication of treatment-resistant pancreatic cancer stem cells
Funding Source: UTMDACC Khalifa Bin Zayed Al Nahyan Center for Pancreatic Cancer Research
Role: Principal Investigator
Duration: 7/1/2013 - 6/30/2016

Last updated: 7/28/2016